Patents by Inventor J. Mark Quillan

J. Mark Quillan has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Melanocortin receptor antagonists and modulations of melanocortin receptor activity
    Patent number: 6953779
    Abstract: The clinical outcome of disseminated melanoma is grim. Small molecular weight antagonists (preferably about seven amino acid residues) specific for MCR on melanoma cells are provided for the therapy of melanoma as well as in other conditions where modulation of MCR is of clinical significance. A particularly preferred antagonist is p-anisoyl-[D-Arg6,9, D-Lys11, D-Leu12] dynorphin A(6-12)-NH2, which is an excellent antagonist of the MCR-1 receptor.
    Type: Grant
    Filed: May 4, 2001
    Date of Patent: October 11, 2005
    Inventors: Edward T. Wei, J. Mark Quillan, Wolfgang Sadée, Guennady P. Vlasov, Jaw Kang Chang
  • Antagonists of alpha-melanocyte stimulating hormone and methods based thereon
    Patent number: 6602856
    Abstract: Peptide antagonists of &agr;-melanocyte stimulating hormone are disclosed, together with methods of inhibiting the effects of &agr;-melanocyte stimulating hormone on cells or tissues sensitive to that hormone. In particular, methods for lightening the pigmentation of skin and for treating malignant melanoma, as well as kits for practicing the invention are also disclosed.
    Type: Grant
    Filed: January 17, 1995
    Date of Patent: August 5, 2003
    Inventors: J. Mark Quillan, Channa K. Jayawickreme, Michael R. Lerner
  • Melanocortin receptor antagonists and modulations of melanocortin receptor activity
    Publication number: 20020004485
    Abstract: The clinical outcome of disseminated melanoma is grim. Small molecular weight antagonists (preferably about seven amino acid residues) specific for MCR on melanoma cells are provided for the therapy of melanoma as well as in other conditions where modulation of MCR is of clinical significance. A particularly preferred antagonist is p-anisoyl-[D-Arg6,9, D-Lys11, D-Leu12] dynorphin A(6-12)-NH2, which is an excellent antagonist of the MCR-1 receptor.
    Type: Application
    Filed: May 4, 2001
    Publication date: January 10, 2002
    Applicant: The Regents of the University of California
    Inventors: Edward T. Wei, J. Mark Quillan, Wolfgang Sadee, Guennady P. Vlasov, J.K. Chang
  • Melanocortin receptor antagonists and modulations of melanocortin receptor activity
    Patent number: 6228840
    Abstract: The clinical outcome of disseminated melanoma is grim. Small molecular weight antagonists (preferably about seven amino acid residues) specific for MCR on melanoma cells are provided for the therapy of melanoma as well as in other conditions where modulation of MCR is of clinical significance. A particularly preferred antagonist is p-anisoyl-[D-Arg6,9, D-Lys11, D-Leu12] dynorphin A(6-12)-NH2, which is an excellent antagonist of the MCR-1 receptor.
    Type: Grant
    Filed: February 27, 1998
    Date of Patent: May 8, 2001
    Inventors: Edward T. Wei, J. Mark Quillan, Wolfgang Sadée, Guennady P. Vlasov